Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines

Table 1 Myeloma patient characteristics

Pt #	Age (yrs)	Sex	Ethnicity	WBC^a(10³/μl)	Plasma cells (%)	BM^baspirate done	Outcome of treatment
1	62	Male	White	3.6	7	At diagnosis	NA^c
2	53	Female	Black	2.0	74	Post bortezomib + doxorubicin + lenalidomide + dexamethasone	Progressive
3	53	Female	White	6.3	4	Post 3 cycles bortezomib + dexamethasone	Near complete remission
4	76	Female	White	4.4	2	Post cyclophosphamide + lenalidomide + dexamethasone	Progressive
5	58	Female	Hispanic	9.1	8	At diagnosis	NA
6	64	Female	White	12.5	49	At diagnosis	NA
7	71	Male	White	3.9	32	NA	NA
8	76	Male	White	4.9	36	post 1 yr auto stem cell transplant	Progressive

ISSN: 1756-8722